How AI And ML Can Transform Clinical Trial Conduct

Undoubtedly, 2023 will be etched in history as the pivotal year for the ascendance of generative artificial intelligence (AI) and machine learning (ML) in both the technology and pharmaceutical sectors. Much like the exponential rise of digital and decentralized trials in 2020, AI and ML are ushering in a transformative era, redefining the boundaries of drug and treatment development.

In light of recent FDA publications outlining a forward-looking framework, sponsors and Contract Research Organizations (CROs) worldwide are fervently exploring ways to fortify their drug development strategies. As these advancements unfold at an unprecedented pace, this article offers an insightful overview of the multifaceted applications of AI and ML in the realm of clinical research, shedding light on their profound impact and potential to revolutionize the industry.